Vascular endothelial growth factor~VEGF!-A interacts with the receptor tyrosine kinases VEGF-R1 and R2, and the importance of this interaction in endothelial cell~EC! function and blood vessel development has been well documented.
The formation of blood vessels, either de novo during vasculogenesis or from existing vessels via a mechanism referred to as angiogenesis, is coordinated by a set of critical receptor-ligand interactions that regulate various aspects of endothelial cell~EC! function. In particular, recent gene knockout studies have established a key role for the interaction of vascular endothelial growth factor~VEGF or VEGF-A! with the receptor tyrosine kinases RTKs! VEGF-R1~Flt-1! and VEGF-R2~Flk-1!~Flamme et al., 1997; Hanahan, 1997!. Similarly, gene knockout studies have highlighted the importance of the angiopoietins and their interaction with the RTK Tie 2, and the interaction of some Eph receptors with their ligands, in vascular development~Gale & Yancopoulos, 1999!. Additional factors such as the fibroblast growth factors~FGFs! and platelet-derived growth factor~PDGF!, while influencing EC proliferation and migration~Thomas et al., 1985; Ishikawa et al., 1989 ! may play a more important role in the recruitment of smooth muscle cells and fibroblasts to the vessel structure.
Of the growth factors that regulate blood vessel formation and function, VEGF-A is arguably the most extensively characterized. It is a secreted dimeric glycoprotein with at least four alternate splice forms that have proliferative, chemotactic, and anti-apoptotic effects on EC in vitro~Houck et al., 1991!, and well-documented angiogenic activity in a variety of in vivo and ex vivo models Ferrara et al., 1991 !. Based on sequence and structural homology, four additional proteins are now included within the VEGF family: placenta growth factor~PLGF!~Maglione et al., 1991!, VEGF-B Grimmond et al., 1996; Olofsson et al., 1996 !, VEGF-C~Joukov et al., 1996 !, and VEGF-D~Achen et al., 1998 !. While VEGF-A binds VEGF-R1 and -R2, PLGF and VEGF-B bind only to VEGF-R1. In contrast, VEGF-C and D bind VEGF-R2 and a third receptor, Flt-4 or VEGF-R3, restricted to lymphatic endothelium~Joukov Achen et al., 1998 !. The functional significance of the distinct receptor binding characteristics of the additional family members remains unclear. Although various activities of VEGF-A have been assigned to either VEGF-R1 or VEGF-R2-mediated signaling~Hanahan, 1997!, this simple demarcation must be reconciled with recent evidence that VEGF-R1 may act as a nonsignal transducing decoy receptor, at least during embryonic development~Hiratsuka et al., 1998!. Both VEGF-C and D have the capacity to influence lymphatic development through interaction with VEGF-R3, and such activity has been demonstrated for VEGF-C Jeltsch et al., 1997!. Furthermore, in addition to the three RTKs, selected splice forms of VEGF-A and PLGF and both splice forms of VEGF-B~Makinen et al., 1999! interact with the semaphorin receptor Neuropilin-1~Soker et al., 1998!, and the functional significance of this interaction also remains to be determined.
In addition to a homodimeric species, VEGF-A has also been shown to form heterodimers with both PLGF and VEGF- B~Cao et al., 1996; Olofsson et al., 1996 !. VEGF-B has a wide tissue distribution that overlaps substantially with that of VEGF-A~Olofs-son et al., 1996!. There are two isoforms~VEGF-B 167 and VEGF-B 186 ! that arise through use of an alternative splice-acceptor site within exon 6, resulting in an insertion of 101 base pairs and a frameshift~Grimmond et al., 1996!. Thus, although both isoforms have an identical NH 2 -terminal domain, they differ at the COOHterminal domains with only the VEGF-B 167 splice form retaining the capacity to bind heparin. Recombinant VEGF-B~both isoforms! derived from transfected mammalian cells has been demonstrated to bind VEGF-R1, and this binding was blocked by an excess of VEGF-A~Olofsson et al., 1998!. In addition, mutational analysis suggested that both VEGF-A and VEGF-B share a common receptor-binding domain~Olofsson et al., 1998!. Further characterization of VEGF-B biological activity, however, has been hampered by the expression of endogenous VEGF-A in most mammalian cell lines used to make recombinant proteins, leading to the purification of heterodimeric species. To overcome this issue, we have developed a protocol for the expression and purification of refolded recombinant VEGF-B 167 from Escherichia coli. The resulting purified homodimer was demonstrated to bind to VEGF-R1 and to compete with VEGF-A for binding to this receptor.
Results

Solubilization and purification of inclusion bodies-derived VEGF-B 167
Using the pET15b vector, VEGF-B 167 was expressed in E. coli as an NH 2 -terminal His 6 tagged protein. Following fermentation, inclusion bodies~IBs! were isolated, washed, and then solubilized in preparation for metal~Ni 2ϩ ! affinity chromatography under both denaturing and reducing conditions. To confirm the identity of eluted proteins, an identical gel was subjected to Western blot analysis using a polyclonal antibody raised against an NH 2 -terminal VEGF-B 167 peptide. SDS-PAGE analysis of the Ni 2ϩ affinity purified protein revealed a major band with an apparent molecular weight of 25 kDa~Fig. 1, lane C!. Additional prominent bands with apparent molecular weights of 20 and 14 kDa were also identified. Western blot analysis using an NH 2 -terminal specific antibody suggested that the short forms of VEGF-B 167 eluted from the Ni 2ϩ column were truncated at the COOH-terminus. A putative heparin binding domain, which is highly charged, exists in the COOH-terminus of VEGF-B 167~G rimmond et al., 1996!. On this basis, the charge of the truncated VEGF-B 167 species is expected to be substantially different from the full-length form. The Ni 2ϩ affinity purified VEGF-B 167 was applied to a SP-Sepharose cation exchange column under denaturing conditions. A salt gradient separated truncated VEGF-B 167 species from the full-length form Fig. 1 , lane D!. Following Ni 2ϩ affinity chromatography, the yield of protein from 1 L of starting fermentation material was estimated to be 41 mg by Bradford assay. The yield following ion exchange was ;25 mg per liter of starting culture.
Refolding and purification of dimeric VEGF-B 167
Purified monomeric VEGF-B 167 obtained from the cation exchange step was dialyzed against a buffer containing 0.5 M GdCl and a combination of 5 mM cysteine01 mM cystine as the disulfide oxido-shuffling reagent overnight. Under nonreducing conditions, SDS-PAGE and Western blot analysis indicated significant conversion to dimer with monomeric and higher oligomeric forms also present~Fig. 2, lane A!. The protein solution was dialyzed overnight against 0.1 M acetic acid.
Purification of dimeric VEGF-B 167
The refolded and acidified protein was concentrated 10-fold and applied to a polyhydroxymethyl A hydrophilic column. Following gradient elution, fractions containing primarily dimeric protein were identified by SDS-PAGE analysis, pooled, and applied to a C8 reversed-phase column. Analytical RP-HPLC profiles of protein before and following each of these chromatographic steps are shown in Figure 3 . Under nonreducing conditions the purified VEGF-B 167 appears as two closely spaced bands on a SDS-PAGE gel~Fig. 2, lane B!, which migrates as a single species of 25 kDa upon reduc- The purified dimeric VEGF-B 167 was subjected to NH 2 -terminal amino acid sequence analysis~Hewlett Packard, Palo Alto, California!, resulting in a single sequence consistent with the translated cDNA sequence of VEGF-B 167 . MALDI mass spectrometry revealed a single dimeric species with molecular weight 42,724 Da, consistent with full-length dimeric VEGF-B 167~M W 42,761 Da!. Yields of pure dimer were approximately 2-4 mg0L of starting material.
Receptor binding analysis
To confirm correct refolding of VEGF-B 167 , its binding to the VEGF receptors VEGF-R1 and R2 was assessed using both biosensor analysis and ELISA-based assays. For biosensor analysis, VEGF-B 167 and control VEGF-A 165 were immobilized to individual channels of CM5 sensorchip using NHS-EDC chemistry. A blank derivatized channel was used as an additional control. Interaction with VEGF-R1, and subsequently VEGF-R2, was monitored simultaneously on all channels. As expected, both VEGF-A and -B were observed to interact with VEGF-R1 with similar kinetics~Fig. 4!. In contrast, while VEGF-R2 interacted with VEGF-A, no interaction with VEGF-B 167 was observed.
Nonspecific binding of VEGF-B to the sensor surface, presumably as a result of its basic nature~pI 9.2!, precluded competition studies in which the VEGF-R1 signal was competed with solution phase VEGF-B 167 . To further study the interaction of refolded VEGF-B 167 with VEGF-R1, two ELISA based approaches were used. In the first approach, VEGF-B 167 was biotinylated and the interaction of this protein with plate bound VEGF-R1 and -R2 examined. In agreement with biosensor data, the biotinylated VEGF-B 167 interacted with VEGF-R1 but not VEGF-R2 over the range of 1 to 100 ng0mL~results not shown!.
A second ELISA format was used to determine the ability of refolded VEGF-B 167 to compete with VEGF-A for binding to plate bound VEGF-R1. In these experiments, VEGF-R1-bound VEGF-A was detected with a VEGF-A-specific polyclonal antibody. The binding of VEGF-A to plate-bound VEGF-R1 was shown to be dependent on both the concentration of VEGF-A and the concentration of VEGF-R1 used to coat the plate~Fig. 5A!. We then examined the ability of VEGF-B 167 to compete with VEGF-A~10 ng0mL! for binding to VEGF-R1~Fig. 5B!. The refolded VEGF-B 167 effectively competed with VEGF-A with an IC 50 of ;25 ng0mL. 
Discussion
For cytokines with complex secondary structure such as those that incorporate a cystine-knot motif, mammalian cell expression systems are often the method of choice for production of recombinant protein. The VEGF family of cytokines are characterized by a cystine knot motif at one end of a conserved central four-stranded b-sheet within each monomer, which dimerize in an antiparallel side-by-side orientation~Muller et al., 1997!. In attempting to express and purify VEGF-B from both 293T and CHO cells, two significant problems were encountered. First, a high proportion of the expressed protein aggregated within the cell. Second, the secreted protein was contaminated with a heterodimeric species that incorporated endogenous CHO or 293T-derived VEGF-A. This is consistent with previous studies where the proliferation of endothelial cells induced with 293-derived recombinant VEGF-B was subsequently attributed to contaminating heterodimers incorporating endogenous VEGF-A~Olofsson et al., 1996!. The expression of VEGF-B 167 in a yeast system was also explored; however, aggregation of the protein was also a significant problem. Because the closely related VEGF-A has been expressed in E. coli and successfully refolded from inclusion bodies~Siemeister et al., 1996!, this approach was adopted for VEGF-B 167 .
Following induction during fermentation, full-length VEGF-B was expressed at ;10-20% of whole-cell protein. The presence of an NH 2 -terminal His 6 -Tag suggested that the truncated form, which eluted with the full-length protein after Ni 2ϩ chromatography, was unlikely to be modified at the NH 2 -terminus. The exact cause of the truncation remains unclear. However, a variety of strategies, including modification of the fermentation protocol, use of protease inhibitors, and modification of the cDNA sequence to incorporate E. coli preferred codons~Sharp et al., 1988! at selected sites and to remove acid-labile sites, did not alter levels of truncated protein~results not shown!. Preliminary refolding experiments indicated that failure to remove the truncated form could lead to the formation of heterodimeric species. As a result, it was necessary to incorporate a step that separated full-length VEGF-B 167 from the truncated form prior to refolding. This was achieved using cation exchange chromatography under denaturing conditions. It is likely that the truncated form is missing either all or a part of the highly charged putative COOH-terminal heparin-binding domain present in full-length VEGF-B 167 . Initial attempts to remove the truncated form of the protein involved the use of a heparin sepharose affinity column under highly denaturing and reducing conditions~6 M urea, 20 mM DTT!. However, because it was found that the interaction between the monomeric protein and the heparin was largely ionic under these conditions, it was replaced by cation exchange chromatography, which is far more cost-effective, and gives rise to greater recovery of full-length monomer.
For a disulfide-linked dimeric protein purified as a monomer from solubilized inclusion bodies, refolding represents the critical step. An array of refolding buffers was assessed to identify conditions that would yield dimeric VEGF-B 167 using either dialysis or dilution based refolding protocols. The yield of dimer~as determined by SDS-PAGE and Western blot analysis! was found to be highly dependent on the incorporation of low molecular weight additives, such as 0.5 M GdCl or 0.4 M arginine~Rudolph & Lilie, 1996!. Attempts to refold in the absence of additives resulted in highly aggregated protein with little or no dimer. In addition to these additives, the large number of potential inter-and intramolecular disulfide pairings necessitated the use of an oxido shuffling reagent to allow energetically favored refolding conformations to be sampled. Although the glutathione oxido pair was effective, the cysteine0cystine combination~Rudolph, 1990! resulted in cleaner product with a lower level of aggregation.
These buffer conditions are conducive to the formation of a molten globule intermediate. Subsequent acidification of the protein effectively minimizes disulfide shuffling, thereby stabilizing the protein conformation. This can be seen chromatographically, where separation of the dimeric species from monomeric and aggregate species is not achieved by RP-HPLC when dialyzed solely against the refolding buffer~Fig. 6!. However, the further dialysis against 0.1 M acetic acid can result in dimeric protein that can be separated chromatographically~Fig. 6! and further purified.
Because both aggregate and monomeric forms of VEGF-B 167 are by-products of the refolding process, chromatographic techniques were required to separate these from the dimer. Attempts to purify dimeric VEGF-B 167 using conventional chromatographic resins in aqueous buffers were unsuccessful, presumably due to nonspecific binding associated with the COOH-terminal heparin binding domain. A combination of polyhydroxymethyl A hydrophilic chromatography, which separates monomer from dimer0 aggregate, followed by reversed-phase chromatography using C8 resin, which resolves dimer from aggregate, was effective.
Previous studies describing the receptor binding characteristics of VEGF-B used recombinant protein purified from mammalian cells in precipitation studies with Ig-Fc chimeric receptors~R1, R2, and R3! and protein-A coupled to sepharose~Olofsson et al., 1998!. These studies demonstrated that both isoforms of VEGF-B bound to VEGF-R1 but not VEGF-R2 or R3. Similar studies were undertaken using the E. coli-derived VEGF-B. However, high background binding was observed to sepharose that could not be effectively blocked. As a result, alternative approaches were pursued, including biosensor and ELISA based analyses. Both methods confirmed previous observations with the E. coli derived protein interacting with VEGF-R1, but not VEGF-R2. Although the direct measurement of the binding constant for E. coli derived VEGF-B 167 :VEGF-R1 complex has not been established, the ELISA based competition experiments indicate that it binds with a similar affinity to VEGF-A.
The biosensor and ELISA studies clearly suggest that the E. coli derived VEGF-B 167 has been refolded to the correct conformation. However, to further confirm this, it will be necessary to assess biological activity in cell based in vitro assays or in appropriate in vivo models. Useful in vitro cell-based assays for VEGF-R1 ligands are problematic. Reports of activity on endothelial cells, including stimulation of proliferation~Olofsson et al., 1996! and induction of mRNA for uPA and PAI-1~Olofsson et al., 1998! have subsequently been attributed to contaminating heterodimer and lipopolysaccharide, respectively. More recently there have been reports of PLGF activity on monocytes~Clauss et al., 1996!, SMC Keiser, 1998!, and osteoclasts~Niida et al., 1999 !. PLGF also interacts with R1 but not R2 and presumably VEGF-B will reproduce these effects. Studies looking at the interaction of recombinant VEGF-B with these cell types are currently in progress. In vivo approaches to the analysis of VEGF-B function are focussed on models of ischemia given that VEGF-R1, but not R2 is potently up-regulated in ischemic tissue~Gerber et al., 1997!.
Materials and methods
Plasmid preparation
The coding region of mature human VEGF-B 167 was amplified using PCR~94 8C02 min-one cycle; 94 8C015 s, 60 8C015 s, 72 8C02 min-35 cycles; 72 8C05 min-one cycle; Stratagene Pfu turbo; Corbett Research PC-960-G thermal cycler! to introduce in frame Nde I and BamH1 restriction enzyme sites at the 59 and 39 ends, respectively, using the following oligonucleotides: 59Oligo 59-ATATCATATGGCCCCTGTCTCCCAGCCTGATGC-39 39Oligo 59-TATAGGATCCTCACCTTCGCAGCTTCCGCACCT-39.
The resulting PCR derived DNA fragment was gel purified, digested with Nde I and BamH1, gel purified again, and then cloned into Nde I0BamH1 digested pET15b~Novagen, Madison, Wisconsin!. Following transformation of E. coli with the pET15b-VEGF-B 167 construct, expressed VEGF-B 167 has an additional 21 amino acids at the NH 2 -terminus that incorporates a hexa-His~His 6 ! tag and a thrombin cleavage site. 
Expression of His 6 -tagged VEGF-B 167
pET15b-VEGF-B 167 was transformed into BL21~DE3! GOLD E. coli~Stratagene, La Jolla, California! using an Electroporator BioRad, Hercules, California! according to the manufacturer's instructions. The transformation reaction was plated onto LB ampicillin plates and incubated overnight at 37 8C. Ampicillin-resistant colonies were picked, grown overnight, and DNA extracted using a standard miniprep protocol~Rapid Pure Miniprep Kit, Bio 101, La Jolla, California!. Miniprep DNA was analyzed using the restriction enzymes BamH1 and Nde1.
For preparation of a seed culture, 5 mL LB broth was inoculated with pET15b-VEGF-B 167 transformed BL21~DE3! GOLD from a glycerol stock. The culture was allowed to grow at 37 8C with continuous shaking to an OD 600 of 0.7 and stored at 4 8C until required. For protein production, 1 L of LB medium was inoculated with a 5 mL seed culture and incubated at 37 8C with continuous shaking. Cells were grown to OD 600 0.7~typically 5 h! and induced with 1 mM IPTG~Pharmacia, Uppsala, Sweden! for 2 h. Yields were typically 3-4 g wet cells per liter of culture. Cells were pelleted by centrifugation and pellets stored frozen at Ϫ80 8C until required.
Isolation of His 6 -tagged VEGF-B 167 inclusion bodies
Frozen cell pellets were thawed and 3 mL lysis buffer~50 mM Tris-HCl, pH 8.0, 1 mM EDTA, 100 mM NaCl! was added per gram of cells. Once thoroughly mixed, 10 mM PMSF~40 mL! and 20 mg0mL lysozyme~40 mL! were added per gram of cells. The solution was mixed thoroughly and allowed to stand for 30 min at 37 8C. Deoxycholic acid~4 mg0g cells! was added and the solution mixed until viscous. DNase I~1 mg0mL: 20 mL0g of cells! was mixed with the cell lysate and allowed to stand for 30 min at 37 8C, or until no longer viscous. Insoluble material was pelleted by centrifugation at 13,500 rpm for 30 min at 4 8C.
Pelleted insoluble material was resuspended in 35 mL of 100 mM Tris-HCl, pH 7.0, 5 mM EDTA, 10 mM DTT, 2 M urea, 2% v0v Triton-X 100 per liter of starting fermentation product. The suspension was placed on ice and subjected to sonication~6 ϫ 1 min on high power with 2 min intervals!, followed by centrifugatioñ 13,500 rpm, 4 8C! for 30 min. This wash method was repeated two additional times. After the third wash, the pelleted material was resuspended in 25 mL of 100 mM Tris-HCl, pH 7.0, 5 mM EDTA, 10 mM DTT per liter of starting fermentation product, sonicated for 1 min at 4 8C and centrifuged~13,500 rpm, 4 8C! for 30 min. This second wash step was also repeated twice. The washed inclusion bodies were pelleted as above and stored at Ϫ70 8C until required.
Metal affinity chromatography
The washed inclusion bodies were solubilized by the addition of 10 mL 6 M guanidinium chloride~GdCl!, 0.1 M NaH 2 PO 4 , 10 mM Tris-HCl, pH 8.5. To completely solubilize inclusion bodies, the suspension was placed on ice and subjected to sonication for 1 min at high power. The solution was centrifuged at 18,000 rpm for 15 min to separate insoluble material. The solution was reduced by the addition of 20 mM DTT and allowed to stand at 37 8C for 30 min.
A 50 mL metal chelating column was prepared using Chelating Sepharose Fast Flow resin~Pharmacia!. The column was washed with three column volumes H 2 O, followed by five column volumes of 0.1 M NiCl 2 . A further three column volumes of H 2 O followed by three column volumes of 6 M GdCl, 0.1 M NaH 2 PO 4 , 10 mM Tris-HCl, pH 8.5 were used to equilibrate the column. The reduced protein solution was loaded onto the column at 10 mL0 min. The column was then washed with five column volumes of 8 M urea, 0.1 M NaH 2 PO 4 , 10 mM Tris-HCl, pH 8.5, followed by five column volumes of 8 M urea, 0.1 M NaH 2 PO 4 , 10 mM Tris-HCl, pH 6.3. The bound fraction was eluted with 6 to 10 ϫ 5 mL volumes of 8 M urea, 0.1 M NaH 2 PO 4 , 10 mM Tris-HCl, 0.5 M imidazole, pH 5.9.
Cation exchange chromatography
Pooled fractions from Ni 2ϩ purification were reduced with 40 mM DTT for 1 to 2 h. A 50 mL SP-Sepharose column was prepared by equilibrating with five column volumes of 6 M urea, 10 mM NaH 2 PO 4 , 10 mM Tris-HCl, pH 5.8~Buffer A!. The protein solution was diluted threefold with Buffer A and loaded onto the column at 10 mL0min. Full-length monomeric VEGF-B 167 was separated from the truncated form using a linear gradient formed between Buffer A and 6 M urea, 10 mM NaH 2 PO 4 , 10 mM TrisHCl, 1 M NaCl, pH 5.8~Buffer B!.
Refolding and purification of dimeric VEGF-B 167
Fractions containing full-length VEGF-B 167 were pooled and diluted to 100 mg0mL with 6 M urea, 0.1 M NaH 2 PO 4 , 10 mM Tris-HCl, 1 mM EDTA, 20 mM DTT, pH 8.5, then dialyzed against 100 mM Tris-HCl, 5 mM cysteine, 1 mM cystine, 0.5 M GdCl, 2 mM EDTA, pH 8.5, overnight at room temperature. The solution was then dialyzed against 0.1 M acetic acid for approximately 24 h and filtered through a 0.22 mM cellulose acetate filter~Corning, Corning, New York! to remove particulate matter.
To separate dimeric VEGF-B 167 from mono-and multimeric species the acidified protein solution was diluted fivefold with 80% v0v n-propanol, 10 mM NaCl, pH 2.0~Buffer C!, and loaded onto a Polyhydroxymethyl A hydrophilic column~PolyLC!. A linear gradient was formed between Buffer C and 10 mM NaCl, pH 2.0~Buffer D!. Fractions containing dimeric VEGF-B 167 were combined, diluted fourfold with water, and loaded onto a C8 reversed-phase column~Brownlee! pre-equilibrated at 45 8C with 0.15% TFA~Buffer E! using a GOLD Beckmann system. A linear gradient was formed between Buffer E and 0.13% v0v TFA, 60% v0v acetonitrile~Buffer F!. Fractions containing dimeric VEGF-B 167 were pooled, diluted, and reapplied to the C8 column. The protein was eluted with Buffer F to minimize sample dilution.
Biosensor analysis of receptor binding
The binding of VEGF-B 167 to VEGF-R1 and VEGF-R2 was monitored by surface plasmon resonance~Biosensor 2000, Biacore, Uppsala, Sweden!. VEGF-B 167 and VEGF-A 165 were immobilized to a CM dextran chip using amine coupling chemistry according to the manufacturer's instructions. Briefly, 35 mL NHS0EDC~1:1! was injected onto the sensorchip at a flow rate of 5 mL0min to activate the sensor surface. VEGF-A 165~P eprotech, Rocky Hill, New Jersey, 100 mg0mL! was diluted 10-fold with 20 mM sodium acetate, pH 4.2~35 mL! and injected directly onto the sensor surface. Post-coupling, 50 mM diaminoethane, pH 9.0~35 mL! was used to quench residual activated sites on the sensor surface. Pu-
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rified dimeric VEGF-B 167 was concentrated using RP-HPLC to a final concentration of 200 mg0mL, diluted 10-fold with 20 mM sodium acetate, pH 4.2, and immobilized onto a separate channel on the sensorchip. A derivatized blank flow cell served as a control in these experiments. At the end of each run, the sensorchip surface was regenerated using two sequential cycles of 0.1 M phosphoric acid~30 mL! at a flow of 50 mL0min.
Both VEGF-R1 and -R2 were obtained as chimeric proteins incorporating the human immunoglobulin Fc domain~R&D Systems, USA!. Both were reconstituted in 0.1% v0v BSA in PBS as a stock solution~50 mg0mL! and diluted~1:10! into 20 mM HEPES, 0.15 M NaCl, 0.005% v0v Tween 20, 3.4 mM EDTA, pH 7.4. Receptor binding was simultaneously monitored on VEGF-A 165 , VEGF-B 167 , and control channels at a flow rate of 5 mL0min.
ELISA-based Flt-1 binding assay
Ninety-six well plates~Nunc, Maxisorp, Roskilde, Denmark! were coated with sheep anti-human IgG~Silenus, Melbourne, Australia! overnight at 4 8C~8 mg0mL in PBS, 100 mL0well!. Plates were washed three times~PBS, 0.1% v0v Tween 20, PBS-Tw! and blocked for 1 h at room temperature with a solution containing 1% w0v BSA, 5% w0v sucrose, and 0.05% w0v sodium azide~250 mL0 well!. After washing as above, VEGF-R10Fc~100 ng0mL in PBSTw, 100 mL0well! was added and plates incubated for 90 min at room temperature. After washing, 50 mL0well of VEGF-A 165 was added at the indicated concentration and plates incubated at room temperature for 1 h. In competition experiments, VEGF-B 167 was added 30 min prior to the addition of VEGF-A 165 . After washing, biotinylated anti-VEGF-A 165 antibody~R&D systems, 10 ng0mL in PBS-BTw, 100 mL0well! was added and plates incubated for 1 h at room temperature. Binding of biotinylated antibody was detected by addition of Streptavidin-horseradish peroxidase~Sigma, St. Louis, Missouri, 100 ng0mL, 100 mL0well! for 30 min at room temperature. Complex formation was detected by addition of 50 mL0 well of TMB substrate solution~tetramethylbenzidine, AMRAD, Australia! to each well. After addition of 50 mL of stop solutioñ 0.5 M H 2 SO 4 ! optical density was measured at 450 nm.
SDS-Page
Tris-glycine SDS-PAGE gels~10-20%; Novex, San Diego, California! were run at 25 mA under both nonreducing and reducing conditions and stained for protein using 30% methanol, 10% acetic acid, 0.1% Coomassie Blue R-350. Gels were destained with 30% ethanol, 10% acetic acid.
